Skip to main content
. 2017 Aug 29;14(8):e1002379. doi: 10.1371/journal.pmed.1002379

Fig 5. The cumulative risk of re-presentation with P. vivax malaria by baseline risk factor.

Fig 5

A: primaquine dose category; B: P. vivax mono- or mixed infection; C: gender; D: ethnicity; E: age group; F: year; G: initial treatment as an outpatient or inpatient; H: vivax malaria episode number. (PQ, Primaquine; SD, Single Dose; LD, Low Dose; HD, High Dose).